Valuation : Satellos Bioscience Inc.

Market Cap 193M 166M 156M 142M 266M 18.23B 268M 1.84B 717M 9.31B 724M 708M 30B P/E 2026 *
-4.25x
P/E 2027 * -5.68x
Enterprise Value 91.21M 78.48M 73.64M 67.38M 126M 8.62B 127M 871M 339M 4.41B 343M 335M 14.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.33%
Yield 2026 *
-
Yield 2027 * -
1 day-0.56%
1 week-4.20%
Current month-3.69%
1 month-10.50%
3 months+50.78%
6 months-27.45%
Current year+58.21%
1 week 12.14
Extreme 12.14
13.03
1 month 12.11
Extreme 12.11
14.5
Current year 7.67
Extreme 7.67
18.98
1 year 7.32
Extreme 7.320002
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
20.28
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
18/8/26 Option

Director

10,608 0.0509%
18/8/26 Option

Director

10,608 0.0509%
18/8/26 Option

Director

10,608 0.0509%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%-4.20%+58.21%+161.04% 193M
+0.41%-2.07%+41.26%+95.40% 69.02B
-0.83%+1.03%+43.24%+90.44% 66.32B
+0.04%+4.36%-11.72%+459.54% 27.66B
-0.90%-7.65%+2.45%-15.50% 25.84B
-3.00%-2.90%+39.40%+9.41% 26.54B
-0.20%+1.67%+25.62%-17.69% 20.4B
+3.45%-13.46%+222.69%+389.50% 17.63B
-1.49%-4.88%-0.41%+530.26% 15.15B
+1.03%+7.00%+59.98%+160.03% 14.65B
Average -0.21%-1.66%+48.07%+186.24% 28.34B
Weighted average by Cap. -0.29%-0.83%+41.75%+148.40%

Financials

2026 *2027 *
Net sales - -
Net income -49.06M -42.21M -39.61M -36.24M -67.65M -4.64B -68.18M -469M -182M -2.37B -184M -180M -7.63B -62.88M -54.1M -50.77M -46.45M -86.7M -5.94B -87.38M -601M -234M -3.04B -236M -231M -9.78B
Net Debt -102M -87.42M -82.03M -75.05M -140M -9.6B -141M -970M -378M -4.91B -382M -373M -15.81B -119M -102M -96.08M -87.91M -164M -11.25B -165M -1.14B -443M -5.75B -447M -437M -18.51B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
03/09/26 CAD 12.53 -0.56% 11,519
02/09/26 CAD 12.60 -1.95% 8,574
01/09/26 CAD 12.85 -1.23% 4,221
31/08/26 CAD 13.01 +7.43% 29,635
28/08/26 CAD 12.11 -7.42% 9,283
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.53CAD
Average target price
17.67CAD
Spread / Average Target
+40.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock